Pharma News

J&J is the latest pharma company to announce a major US investment, committing to a $55bn influx in the next four years. Johnson & Johnson Innovative Medicine (J&J) is significantly expanding ...

China’s National Medical Products Administration (NMPA) has granted conditional approval for Hutchmed’s Tazverik (tazemetostat) to treat adults with relapsed or refractory (R/R...

Sanofi is continuing its immunology pipeline push with an agreement to acquire Dren Bio’s bispecific antibody  n a deal whose value could rise to $1.9bn. Sanofi’s move for Dren Bio’s c...

Johnson & Johnson (J&J) has received US Food and Drug Administration (FDA) approval for its interleukin 23 inhibitor, Tremfya (guselkumab), to treat moderately to severely acti...

Poxel Announces Positive Results from a Preclinical Study for PXL065, a Proprietary Deuterium-Stabilized R-Stereoisomer of Pioglitazone, in Hypertrophic Cardiomyopathy

KNOXVILLE, Tenn. (WVLT) - At the Metro Drug Coalition in Knoxville, they see addiction walk through the door every day.

Sona Nanotech Inc. has released new preclinical data demonstrating the efficacy of its Targeted Hyperthermia Therapy (THT) in inhibiting tumor growth in an immunotherapy-resistant colorectal c...

Since becoming only the second Alzheimer’s-modifying drug to gain American FDA approval in 2023, sales of lecanemab, known by its brand name Leqembi, have risen steadily, reaching $87-million USD in...

Pfizer and Arvinas have shared promising top-line results from a late-stage study of their investigational protein degrader vepdegestrant in a subset of breast cancer patients.

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the poster pr...

Johnson & Johnson (JNJ) announced Tuesday that the U.S. Food and Drug Administration (FDA) has granted investigational nipocalimab Fast Track designation (FTD) for the treatmen...

The findings of this model support KIO-104 as a promising therapeutic candidate for both the prevention and treatment of PVR.